PL1831699T3 - Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek - Google Patents

Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek

Info

Publication number
PL1831699T3
PL1831699T3 PL05820913T PL05820913T PL1831699T3 PL 1831699 T3 PL1831699 T3 PL 1831699T3 PL 05820913 T PL05820913 T PL 05820913T PL 05820913 T PL05820913 T PL 05820913T PL 1831699 T3 PL1831699 T3 PL 1831699T3
Authority
PL
Poland
Prior art keywords
ngal
determination
renal disorders
neutrophil gelatinase
associated lipocalin
Prior art date
Application number
PL05820913T
Other languages
English (en)
Inventor
Lars Otto Uttenthal
Margarita Ghiglione Juanes
Kristian Bangert
Original Assignee
Antibodyshop As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36011033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1831699(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antibodyshop As filed Critical Antibodyshop As
Publication of PL1831699T3 publication Critical patent/PL1831699T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL05820913T 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek PL1831699T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63750304P 2004-12-20 2004-12-20
US71930705P 2005-09-21 2005-09-21
PCT/DK2005/000806 WO2006066587A1 (en) 2004-12-20 2005-12-20 Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders
EP05820913A EP1831699B1 (en) 2004-12-20 2005-12-20 Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders

Publications (1)

Publication Number Publication Date
PL1831699T3 true PL1831699T3 (pl) 2010-04-30

Family

ID=36011033

Family Applications (2)

Application Number Title Priority Date Filing Date
PL05820913T PL1831699T3 (pl) 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek
PL18195687T PL3489689T3 (pl) 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń zaburzenie nerki

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18195687T PL3489689T3 (pl) 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń zaburzenie nerki

Country Status (17)

Country Link
US (3) US20090170143A1 (pl)
EP (4) EP2128625B1 (pl)
JP (1) JP4741603B2 (pl)
KR (1) KR100971305B1 (pl)
CN (1) CN101163971B (pl)
AT (1) ATE448484T1 (pl)
AU (1) AU2005318689B2 (pl)
CA (1) CA2591113C (pl)
DE (1) DE602005013288D1 (pl)
DK (3) DK1831699T3 (pl)
ES (4) ES2703434T3 (pl)
IL (1) IL183872A (pl)
NZ (1) NZ555926A (pl)
PL (2) PL1831699T3 (pl)
SI (1) SI1831699T1 (pl)
WO (1) WO2006066587A1 (pl)
ZA (1) ZA200705776B (pl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
WO2008017306A1 (en) 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
EP2095106B1 (en) * 2006-11-14 2013-03-20 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
US7842472B2 (en) 2006-11-14 2010-11-30 Alere International Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
CA2670516A1 (en) * 2006-12-20 2008-06-26 Antibodyshop A/S Assessment of patients with sepsis to determine a requirement for therapeutic intervention with an antiinflammatory and/or anticoagulatory agent
ES2530209T3 (es) * 2007-02-23 2015-02-27 Physicians Choice Laboratory Services, Llc Métodos diagnósticos dirigidos a intervención clínica
EP2137538B1 (en) * 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
WO2009059259A2 (en) * 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
EP2215481B2 (en) * 2007-11-15 2017-01-18 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
EP2257813A4 (en) * 2008-03-12 2011-11-02 Univ Columbia NGAL WITH HIGH MOLECULAR WEIGHT AS BIOMARKER FOR CHRONIC KIDNEY DISEASE
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
JP2012501456A (ja) 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
WO2010054025A1 (en) 2008-11-05 2010-05-14 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use
US9476880B2 (en) 2008-11-21 2016-10-25 Future Medical Diagnostics Co., Ltd. Methods, devices and kits for detecting or monitoring acute kidney injury
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
US20100233740A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis
ES2350078B1 (es) * 2009-05-19 2011-11-15 Consejo Superior De Investigaciones Científicas (Csic) Celula del smf modificada geneticamente para sobreexpresar ngal y su uso como medicamento
WO2010148216A1 (en) * 2009-06-17 2010-12-23 The Trustees Of Columbia University In The City Of New York Methods and compositions for diagnosis of urosepsis and urinary tract infection
WO2011017685A1 (en) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Methods and devices for detecting kidney transplant rejection
US20120315649A1 (en) * 2009-08-28 2012-12-13 Astute Medical ,Inc. a corporation Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011053832A1 (en) * 2009-10-29 2011-05-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose sepsis in very low birth weight infants
WO2011084548A2 (en) * 2009-12-15 2011-07-14 King Faisal Specialist Hospital & Research Centre Methods and compositions for detecting recesssive familial fsgs and uses thereof
CN102072960A (zh) * 2010-03-29 2011-05-25 武汉生之源生物科技有限公司 一种样本中中性粒细胞明胶酶相关脂质运载蛋白的检测方法
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
CA2811438A1 (en) * 2010-10-07 2012-04-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102253217B (zh) * 2011-04-07 2013-08-07 武汉生之源生物科技有限公司 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒
TW201250248A (en) * 2011-04-25 2012-12-16 Kyowa Medex Co Ltd Prognostication method of renal failure
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
US20130062516A1 (en) * 2011-09-09 2013-03-14 Hsien-Shou Kuo Diganosis of a renal disease by oxygen and hydrogen isotopes in a biological sample
WO2013106200A1 (en) * 2012-01-11 2013-07-18 J. Craig Venter Institute Metaproteomic method for diagnosis of bacteriuria, urogenital tract and kidney infections from urinary pellet samples
CN102662064A (zh) * 2012-04-26 2012-09-12 苏州照康生物技术有限公司 检测中性粒细胞明胶酶相关脂质运载蛋白的免疫比浊试剂盒及其制备方法
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
CN203441604U (zh) 2013-02-15 2014-02-19 通用电气公司 用于降低燃气涡轮系统中的背压的系统
US9488663B2 (en) 2013-03-14 2016-11-08 Abbott Point Of Care Inc. Electrochemical methods and devices for amending urine samples for immunosensor detection
US9651547B2 (en) 2013-03-14 2017-05-16 Abbott Point Of Care Inc. Electrochemical methods and devices for amending urine samples for immunosensor detection
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
KR101590622B1 (ko) 2013-10-24 2016-02-01 (주)메디컬그룹베스티안 화상 중증도 판단 방법
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
JP6788586B2 (ja) * 2014-11-19 2020-11-25 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． Ｈｎｌを用いる診断方法
CN104502596A (zh) * 2014-12-23 2015-04-08 温州医科大学 一种慢性肾病诊断试剂盒
KR101657881B1 (ko) * 2015-03-16 2016-09-19 대구한의대학교산학협력단 타깃 바이오마커에 고특이적이며 고선택적 결합이 가능한 펩타이드 프로브 및 그를 이용한 급성 및 만성 신장질환 조기진단용 바이오칩
ES2950426T3 (es) 2015-08-12 2023-10-09 Univ Columbia Procedimientos de tratamiento de la depleción de volumen y la lesión renal
TWI581802B (zh) 2015-12-23 2017-05-11 國立臺灣師範大學 嗜中性白血球膠原蛋白質酶相關疏水性蛋白質之製藥用途
EP3184116B1 (en) 2015-12-23 2020-09-16 National Taiwan Normal University Neutrophil gelatinase-associated lipocalin for use in prevention or treatment of polycystic kidney disease
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR102094608B1 (ko) * 2018-08-08 2020-04-23 고려대학교 산학협력단 혈액암의 분류 및 예후 판단에 필요한 정보를 제공하는 방법
CN109781990A (zh) * 2018-12-25 2019-05-21 无锡市人民医院 一种β-痕迹蛋白检测试剂盒及制备方法
KR102293024B1 (ko) * 2020-02-07 2021-08-24 고려대학교 산학협력단 혈액 종양 질환 특이적 바이오마커
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
CN115837103B (zh) * 2022-11-21 2024-11-29 首都医科大学宣武医院 一种基于尿液监测的肾衰控制系统

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635091A (en) * 1970-08-31 1972-01-18 Frederick D Linzer Midstream urine specimen and fractional fluid collectors
IT1074038B (it) * 1976-08-05 1985-04-17 Simes Esteri della epinina
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4357343A (en) * 1981-06-26 1982-11-02 Baxter Travenol Laboratories, Inc. Nutritional composition for management of renal failure
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
US5939272A (en) * 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5200319A (en) * 1989-10-27 1993-04-06 The General Hospital Corporation Diagnosis of glomerulonephritis
JP2912413B2 (ja) * 1990-03-28 1999-06-28 東亜医用電子株式会社 粒度分布作成方法
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
SE9401351D0 (sv) 1994-04-21 1994-04-21 Venge A method for diagnosis
US5552313A (en) * 1994-11-21 1996-09-03 Kansas University DNA encoding mouse phosphotriesterase-related protein
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
US5627034A (en) * 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level
JP4602482B2 (ja) * 1996-05-24 2010-12-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組織再生のモジュレーター
US6020163A (en) * 1997-08-06 2000-02-01 Zymogenetics, Inc. Lipocalin homolog
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
AU5330200A (en) * 1999-06-18 2001-01-09 Michigan State University Method and apparatus for the detection of volatile products in a sample
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
AU2001293964B2 (en) * 2000-10-03 2007-06-14 Rowett Research Institute Method of assaying pyrrole-containing biological compounds
US6564385B2 (en) * 2000-10-06 2003-05-20 Mccarthy Daniel J. Handling device
US7153660B2 (en) * 2000-10-13 2006-12-26 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
FI20010019A7 (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen gastriitin diagnostisoimiseksi
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
DE10120614A1 (de) 2001-04-26 2002-10-31 Sms Demag Ag Kühlplatte
EP1322957B1 (en) * 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US20030119209A1 (en) * 2001-12-21 2003-06-26 Kaylor Rosann Marie Diagnostic methods and devices
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
US6847451B2 (en) * 2002-05-01 2005-01-25 Lifescan, Inc. Apparatuses and methods for analyte concentration determination
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2565701A1 (en) * 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
JP2009527735A (ja) * 2006-02-17 2009-07-30 チルドレンズ メディカル センター コーポレーション 癌に対するバイオマーカーとしての遊離ｎｇａｌ
US20080061149A1 (en) * 2006-09-11 2008-03-13 Colin Tanner Proximity payment card with security interlock
US20090123970A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
DE102008025144A1 (de) * 2008-05-26 2009-12-03 Siemens Aktiengesellschaft Anordnung zur Erhöhung der Lese- und Schreibsicherheit von RFID-Labeln

Also Published As

Publication number Publication date
US20160003851A1 (en) 2016-01-07
KR20070108158A (ko) 2007-11-08
US20090170143A1 (en) 2009-07-02
CN101163971B (zh) 2013-03-20
EP3489689B1 (en) 2020-06-17
ES2703434T3 (es) 2019-03-08
IL183872A (en) 2010-11-30
KR100971305B9 (ko) 2022-07-11
ES2622467T3 (es) 2017-07-06
DE602005013288D1 (de) 2010-05-06
HK1105454A1 (en) 2008-02-15
PL3489689T3 (pl) 2020-11-16
EP3208616A1 (en) 2017-08-23
EP3489689A1 (en) 2019-05-29
AU2005318689A1 (en) 2006-06-29
EP2128625B1 (en) 2017-01-25
CA2591113C (en) 2022-06-21
US20150132772A1 (en) 2015-05-14
DK2128625T3 (en) 2017-05-01
SI1831699T1 (sl) 2010-03-31
EP1831699A1 (en) 2007-09-12
EP2128625A3 (en) 2010-07-07
KR100971305B1 (ko) 2010-07-20
JP2008524610A (ja) 2008-07-10
IL183872A0 (en) 2007-10-31
JP4741603B2 (ja) 2011-08-03
DK3489689T3 (da) 2020-09-07
WO2006066587A1 (en) 2006-06-29
AU2005318689B2 (en) 2010-08-19
CA2591113A1 (en) 2006-06-29
EP1831699B1 (en) 2009-11-11
CN101163971A (zh) 2008-04-16
DK1831699T3 (da) 2010-03-15
ZA200705776B (en) 2007-10-31
ES2818028T3 (es) 2021-04-09
EP2128625A2 (en) 2009-12-02
EP3208616B1 (en) 2018-09-26
NZ555926A (en) 2008-11-28
ES2336345T3 (es) 2010-04-12
ATE448484T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
IL183872A0 (en) Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders
PL2341344T3 (pl) Sposób diagnozowania wielotorbielowatości nerek
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
WO2012018535A3 (en) Wellness panel
WO2007117444A3 (en) Protein detection by aptamers
PL2035835T3 (pl) Sposoby szybkiej oceny ciężkości urazu
ATE554389T1 (de) Apex als marker für lungenkrebs
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
NO20093384L (no) Sykdomsmarkorer
WO2007016367A3 (en) Neoplastic disease-related methods, kits, systems and databases
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
EA201100253A1 (ru) Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний
WO2006092729A3 (en) Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
WO2008099608A1 (ja) 炎症性腸疾患の診断方法
ATE359516T1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs
BRPI0512655A (pt) bioexame de rna
WO2009122367A3 (en) Procollagen c-proteinase enhancer (pcpe) biomarker for bone formation